Prof. Dr. Gül Başaran

• Brustneubildungen 23 Publikationen
  Quelle: OpenAlex / PubMed MeSHPublikationen ansehen
• Neubildungen 6 Publikationen
• Adenokarzinom 4 Publikationen
• Lebertumoren 2 Publikationen
• Duktales Mammakarzinom 2 Publikationen
• Morbus Hodgkin 2 Publikationen
• Rektumneubildungen 2 Publikationen
• Magenneubildungen 2 Publikationen

Medizinische Interessengebiete, die der Arzt im Profil der Einrichtung selbst angegeben hat. Quelle: acibadem.com.tr.

Berufserfahrung

• 2011Acıbadem Sağlık Grubuacibadem.com.tr
• 2001 - 2003Universite Libre de Bruxelles, Cancerologieacibadem.com.tr
• 1999 - 2003Marmara Üniversitesi Tıp Fakültesi / Tıbbi Onkolojiacibadem.com.tr

Ausbildung

• 2003Marmara Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji, Üst Uzmanlıkacibadem.com.tr
• 1999Marmara Üniversitesi Tıp Fakültesi, İç Hastalıkları, Uzmanlıkacibadem.com.tr
• 1994İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, Tıp, Üniversiteacibadem.com.tr

• FachgebietMedizinische Onkologieacibadem.com.trAus der Quelle
• Abteilungsname in der QuelleMeme Kliniği, Lenfödem (Fil Hastalığı) Tedavisiacibadem.com.trAus der Quelle
• EinrichtungAcıbadem Altunizade Hastanesiacibadem.com.trAus der Quelle
• ArbeitsschwerpunktBrustneubildungenAus 23 Publikationen ermittelt · Modellversion —Aus der Quelle
• Publikationen139 PublikationenOpenAlexAus der Quelle
• ORCID0000-0002-0775-6180ORCIDAus der Quelle
• Letzte Synchronisierung4. November 2026 20:57https://www.acibadem.com.tr/doktor/gul-basaran/acibadem.com.tr

1. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

   Therapeutic Advances in Medical Oncology, 2026

   DOI 10.1177/17588359261430583 PMID 41835339 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

2. Abstract PS5-02-08: Impact of Prior T-DM1 Exposure on the Efficacy of Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer

   Clinical Cancer Research, 2026

   DOI 10.1158/1557-3265.sabcs25-ps5-02-08 Quelle: OpenAlex

3. Abstract PS5-05-14: Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

   Clinical Cancer Research, 2026

   DOI 10.1158/1557-3265.sabcs25-ps5-05-14 Quelle: OpenAlex

4. Real-world associations of pathological complete response and survival with neoadjuvant pembrolizumab in early TNBC: a Turkish Oncology Group study

   Scientific Reports, 2026

   DOI 10.1038/s41598-026-47351-7 PMID 41933152 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

5. Abstract PS4-10-28: Neoadjuvant Chemoimmunotherapy in Early-Stage TNBC: Real-World Analysis of Predictors of pCR and Survival

   Clinical Cancer Research, 2026

   DOI 10.1158/1557-3265.sabcs25-ps4-10-28 Quelle: OpenAlex

6. Antibody–drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure

   The Breast, 2026

   DOI 10.1016/j.breast.2026.104785 PMID 41980521 Frei zugänglicher VolltextQuelle: OpenAlex

7. First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.

   Journal of Clinical Oncology, 2026

   DOI 10.1200/jco.2026.44.16_suppl.1002 3 Zitationen (OpenAlex) Quelle: OpenAlex

8. Abstract PS4-01-09: How does proteomics-based prognostic testing compare to genomic tests and online clinical risk prediction tools in early breast cancer patients?

   Clinical Cancer Research, 2026

   DOI 10.1158/1557-3265.sabcs25-ps4-01-09 Quelle: OpenAlex

9. 415O First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Patient-reported outcomes (PROs) from TROPION-Breast02

   ESMO Open, 2026

   DOI 10.1016/j.esmoop.2026.107438 Frei zugänglicher VolltextQuelle: OpenAlex

10. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1639022 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex